Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

BACKGROUND: In randomised clinical trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high cardiovascular risk, as compared to standard care. However, data compar...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cardiovasc Diabetol
Main Authors: Thein, David, Christiansen, Mia Nielsen, Mogensen, Ulrik Madvig, Bundgaard, Johan Skov, Rørth, Rasmus, Madelaire, Christian, Fosbøl, Emil Loldrup, Schou, Morten, Torp-Pedersen, Christian, Gislason, Gunnar, Køber, Lars, Kristensen, Søren Lund
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7339487/
https://ncbi.nlm.nih.gov/pubmed/32631337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01078-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares